Patient-specific tumor immunoglobulin idiotype (Id)

The patient-specific tumor immunoglobulin idiotype is a unique antigenic determinant located within the variable regions of the B-cell receptor (BCR) expressed by malignant B cells (Levy & Miller, 1983, Annu Rev Med). In B-cell malignancies, such as follicular lymphoma or chronic lymphocytic leukemia, the tumor arises from a single transformed clone, meaning every malignant cell displays the same unique idiotype (Kwak et al., 1992, NEJM). This idiotype serves as a true tumor-specific antigen (TSA) because it is absent from normal B cells and other healthy tissues, providing a highly precise target for therapy (Bendandi et al., 1999, Nat Med). Therapeutic strategies primarily focus on active immunotherapy through the development of personalized idiotype vaccines (Inogès et al., 2006, Expert Rev Vaccines). These vaccines are custom-manufactured by isolating the patient's specific idiotype protein and often conjugating it to an immunogenic carrier like Keyhole Limpet Hemocyanin (KLH) to overcome self-tolerance (Schuster et al., 2011, J Clin Oncol). The goal is to stimulate the patient's own immune system to recognize and eliminate the malignant clone while sparing healthy B cells. Despite its high specificity, the clinical application of idiotype-targeted therapies has been limited by the logistical challenges of individual manufacturing and the potential for tumor escape via the selection of idiotype-negative variants (Baskar et al., 2012, Cancer Res).

Other names

B-cell receptor idiotypeTumor-specific idiotypeClonal immunoglobulin idiotypeId antigenSurface immunoglobulin idiotype

Active immunotherapy involving the administration of patient-specific idiotype protein, typically conjugated to an immunogenic carrier like Keyhole Limpet Hemocyanin (KLH) and administered with an adjuvant (e.g., GM-CSF), to induce a polyclonal T-cell and B-cell immune response against the unique variable regions of the malignant B-cell receptor (Kwak et al., 1992, NEJM; Schuster et al., 2011, J Clin Oncol).